While established ABL inhibitors have been instrumental in the treatment of CML and have emerging potentials in solid tumors, treatment with these inhibitors can result in drug resistance. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.